Annamycin Shows Strong Cardiac Safety in Pooled Analysis, Reinforcing Differentiated Profile
MBRX sits 50% above its 52-week low of $1.79.
Summary
Moleculin Biotech reported strong cardiac safety data for its lead drug Annamycin at ASCO 2026, addressing a major limitation of anthracycline chemotherapy and bolstering its ongoing pivotal trial.
Key Events · Product Development and Regulatory · MBRX
-
Positive Cardiac Safety Data for Annamycin
A pooled analysis across five completed clinical trials demonstrated no detectable cardiotoxicity for Annamycin, even at cumulative exposure levels far exceeding conventional anthracycline limits.
-
Independent Validation by Cleveland Clinic
The cardiac safety findings were independently reviewed by Cleveland Clinic cardiology specialists, providing external validation.
-
Reinforces Ongoing Pivotal Trial
This data strengthens the rationale for the ongoing Phase 2b/3 MIRACLE trial for relapsed/refractory AML, with unblinding of initial data expected in June 2026.
-
Addresses Key Anthracycline Limitation
Annamycin's differentiated cardiac safety profile could allow patients to benefit from anthracycline therapy without the traditional cumulative cardiac burden.
Analysis · MBRX · Life Sciences
Moleculin Biotech announced positive cardiac safety data for its lead drug candidate, Annamycin, presented at ASCO 2026. A pooled analysis across five clinical trials showed no detectable cardiotoxicity despite high cumulative exposure, a key differentiator for anthracycline-based therapies. This data, independently reviewed by Cleveland Clinic, significantly de-risks Annamycin and strengthens the rationale for the ongoing pivotal Phase 2b/3 MIRACLE trial, which has unblinding expected in June 2026. For a company with a 'going concern' warning and a need for capital, this positive clinical development is crucial for investor confidence and future financing.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $2.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.6M. The 52-week trading range was $1.79 to $24.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.